MOTS-c vs Slu-Pp-332: Research Literature Comparison
MOTS-c and Slu-Pp-332 appear together in search far more often than they appear together in published methodology. That gap is the useful part.
Compound profiles
MOTS-c in the indexed record
Searching MOTS-c against the PubMed index returns 255 records, a moderate evidence base, alongside 9 registered studies on ClinicalTrials.gov.
Journals represented in the current index include Adv Sci (Weinh), Cardiovasc Drugs Ther, Front Endocrinol (Lausanne), spanning 2022–2025.
- Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination — Adv Sci (Weinh), 2024. PMID: 39321430
- MOTS-c attenuates lung ischemia-reperfusion injury via MYH9-Dependent nuclear translocation and transcriptional activation of antioxidant genes — Redox Biol, 2025. PMID: 40403491
- MOTS-c: Magical Molecule for Diabetic Cardiomyopathy? — Cardiovasc Drugs Ther, 2025. PMID: 40172798
- MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation — Front Endocrinol (Lausanne), 2023. PMID: 36761202
Slu-Pp-332 in the indexed record
Slu-Pp-332 returns 10 indexed records on PubMed, a limited record with no registered studies currently listed on ClinicalTrials.gov.
Publications carrying this compound include ACS Chem Biol, Circulation, Int J Biol Macromol, spanning 2023–2026.
- A Synthetic ERR Agonist Alleviates Metabolic Syndrome — J Pharmacol Exp Ther, 2024. PMID: 37739806
- Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function — Circulation, 2024. PMID: 37961903
- In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential — Rapid Commun Mass Spectrom, 2026. PMID: 41588687
- Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling — Int J Biol Macromol, 2026. PMID: 41850449
Side-by-side research profile
| Parameter | MOTS-c | Slu-Pp-332 |
|---|---|---|
| PubMed indexed records | 255 | 10 |
| Registered studies (ClinicalTrials.gov) | 9 | 0 |
| Literature depth | Moderate | Emerging |
| Handling class | Lyophilised powder | Lyophilised powder |
| Designation | Research use only | Research use only |
Classification and why it matters
MOTS-c and Slu-Pp-332 sit in different structural classes, and that classification is what determines whether a published protocol for one has any bearing on the other. Peptide research compounds are grouped by sequence length, origin and the receptor families the literature associates with them — not by the outcome a reader might be looking for.
Reading across classes is the most common error in a literature review. A protocol developed for MOTS-c describes conditions validated for MOTS-c: concentration ranges, solvent choice, incubation windows and control selection were all established against that compound. Applying those same conditions to Slu-Pp-332 without re-validation produces data that cannot be compared back to the source publication.
Where the two compounds are studied in overlapping models, the published work almost always treats them as separate arms rather than as substitutes. That separation is the useful signal: it indicates the research record does not consider them equivalent.
How the literature differs
The indexed record is not symmetrical between these two compounds. MOTS-c carries 245 more indexed records than Slu-Pp-332, which means published methodology, characterisation data and replication attempts are more readily located for MOTS-c. For a researcher planning a literature review, that asymmetry usually determines which compound has established reference protocols and which requires primary-source work.
Registered study counts (9 vs 0) track a different signal — formal study registration rather than published output — and the two figures frequently diverge.
Physical handling notes
Both arrive lyophilised. Standard practice keeps the unopened vial at -20°C, protected from light, and defers reconstitution until the point of use. Solution-phase stability is the limiting factor in most protocols, not powder-phase stability.
Repeated freezing and thawing is the most common avoidable source of degradation.
Selecting between them for a study design
MOTS-c and Slu-Pp-332 are not interchangeable. They differ in structural class and in the pathways the literature associates with each, so substituting one for the other changes what a model is actually measuring.
Where a protocol cites a specific compound, the cited compound is the one the published result applies to. Where no protocol exists, the compound with the deeper indexed record (MOTS-c) generally offers more methodological precedent.
Frequently asked questions
Which of MOTS-c or Slu-Pp-332 has more published research?
MOTS-c, with 255 indexed PubMed records against 10.
Are MOTS-c and Slu-Pp-332 the same compound?
No. They are structurally distinct research compounds with separate literature records — 255 indexed records for MOTS-c and 10 for Slu-Pp-332.
What is the regulatory status of these compounds?
Neither is an approved drug. Both are supplied strictly for in-vitro laboratory research and are not intended for human or veterinary consumption.
Related references
- MOTS-c — product and lot documentation
- Certificate of analysis & purity testing
- Research reference index
Research use only. The compounds discussed are supplied for in-vitro laboratory research. They are not drugs, are not approved for the diagnosis, treatment, cure or prevention of any condition, and are not intended for human or veterinary consumption.